Lipid Accumulation Product Effectively Predicts Metabolic Syndrome in PCOS

Overview

This meta-analysis of 11 studies with 3720 participants demonstrates that the lipid accumulation product (LAP) is significantly elevated in PCOS patients with metabolic syndrome (MetS) and shows superior predictive accuracy compared to other anthropometric indices. LAP exhibited high sensitivity (87%), specificity (84%), and an AUROC of 0.92 for detecting MetS in PCOS.

Background

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder affecting 10-13% of women of reproductive age, characterized by hyperandrogenism, ovulatory dysfunction, and insulin resistance. PCOS patients have a markedly increased risk of developing metabolic syndrome (MetS), a cluster of metabolic abnormalities including central obesity, dyslipidemia, and insulin resistance. Early identification of MetS in PCOS is critical due to its association with adverse fertility outcomes and increased cardiovascular risk. Current diagnostic criteria for MetS are complex, prompting interest in simpler, cost-effective screening tools such as the lipid accumulation product (LAP), which combines waist circumference and triglyceride levels.

Data Highlights

Key Findings

• LAP is significantly higher in PCOS patients with MetS compared to those without (pooled MD = 2.52, P<0.001).
• Elevated LAP is strongly associated with MetS in PCOS, with a pooled odds ratio of 34.31 (P<0.001).
• LAP demonstrates high diagnostic accuracy for MetS with sensitivity of 87% and specificity of 84%.
• The AUROC for LAP in detecting MetS is 0.92, indicating excellent discriminative ability.
• LAP outperforms other anthropometric and biochemical indicators such as BMI, waist circumference, triglycerides, and abdominal volume index (P<0.001).
• Despite some conflicting reports, this meta-analysis supports LAP as a superior, simple, and cost-effective screening tool for MetS in PCOS.

Clinical Implications

Clinicians should consider incorporating LAP measurement, which requires only waist circumference and triglyceride levels, into routine screening for metabolic syndrome in women with PCOS. Its high sensitivity and specificity facilitate early identification of patients at risk, enabling timely intervention to reduce cardiovascular and metabolic complications. LAP offers a practical and economical alternative to more complex diagnostic criteria.

Conclusion

Lipid accumulation product is a reliable and superior indicator for screening metabolic syndrome in PCOS patients, providing a simple and cost-effective tool to improve early detection and management of metabolic risk in this population.

Related Resources & Content

1. Systematic Review Registration CRD42025638798